On October 7, the Federal Trade Commission approved Teva Pharmaceutical Industries Ltd.'s $6.8 billion purchase of Cephalon Inc., conditioned upon it selling the rights to three generic drugs. Of Counsel Tim Muris and partners Christine Wilson and Ian Conner represented Teva on antitrust issues. Corporate partners David Fox and Jeffrey Symons led the transaction.
To read more, please click here (subscription required).
This article appeared in its entirety in the October 10, 2011 edition of The Deal.